US Edition
Early Camizestrant Therapy Keeps Advanced Breast Cancer in Check
- The phase 3 SERENA-6 trial presented at the 2025 ASCO meeting showed that adding camizestrant to CDK4/6 inhibitor therapy significantly extended progression-free survival in patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer.
- Researchers used liquid biopsies to detect ESR1 mutations in circulating tumor DNA months before clinical progression, allowing an early switch to camizestrant before disease worsened on scans.
- The randomized trial enrolled 315 patients previously treated with aromatase inhibitors and CDK4/6 inhibitors, comparing camizestrant plus continued CDK4/6 inhibition to continued AI plus CDK4/6 inhibition until progression or toxicity.
- Camizestrant improved median progression-free survival to 16.0 months versus 9.2 months with continued AI, with a hazard ratio of 0.44 and a 12-month progression-free survival rate of 60.7% compared to 33.4%.
- These findings suggest camizestrant may become a new standard for managing emerging ESR1 mutations, enabling longer efficacy of first-line therapy and highlighting a novel treatment strategy using early ctDNA monitoring.
13 Articles
13 Articles
Early camizestrant therapy keeps advanced breast cancer in check
Switching to camizestrant, a next-generation oral SERD, significantly prolongs progression-free survival and maintains quality of life in patients with ESR1-mutated, hormone receptor-positive advanced breast cancer. The proactive, biomarker-guided approach allows earlier intervention and may redefine standard care.
New drug slows breast cancer growth
A groundbreaking study has revealed that a new medication may significantly slow the growth of breast cancer tumors potentially postponing the need for chemotherapy. In the SERENA-6 trial researchers observed that a drug called camizestrant effectively inhibits the ability of cancer cells to grow by blocking hormones that fuel their development. Scientists described this as the first global study to demonstrate how early detection of treatment r…
AstraZeneca Drug Could Help Keep A Common Breast Cancer At Bay - Data Intelligence
Listen to the article 7 min This audio is auto-generated. Please let us know if you have feedback. CHICAGO — Too often, cancer has a way of evading treatment. Tumors that were held in check begin to spread anew, forcing doctors to try different drugs in a desperate race to keep malignant cells from multiplying. For a common type of breast cancer, this usually happens because of changes in a gene called ESR1. Mutations there can drive cancer gro…
AstraZeneca's SERENA-6 Trial Marks Breakthrough in Breast Cancer Treatment
WILMINGTON, DE — Groundbreaking results from AstraZeneca’s Phase III SERENA-6 trial reveal a significant leap forward in the treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer. The trial demonstrated that switching to AstraZeneca’s camizestrant combined with a CDK4/6 inhibitor reduced the risk of disease progression or death by 56% compared to standard aromatase inhibitor-based treatment. This study is the first to…
AstraZeneca's Camizestrant Shows Promise in Prolonging Treatment Benefits for Common Breast Cancer
AstraZeneca’s experimental drug camizestrant has demonstrated promising results in extending the benefits of initial breast cancer treatment, according to new data presented at the American Society of Clinical Oncology’s annual meeting. The study focused on patients with hormone receptor-positive, HER2-negative advanced breast cancer, which accounts for approximately 70% of breast cancer cases. These patients are typically treated with hormone t…
Coverage Details
Bias Distribution
- 67% of the sources are Center
To view factuality data please Upgrade to Premium
